Press News

Press News

2013.04.09 Notice Regarding Equity Investment in Retina Institute Japan A stock subscription agreement has been concluded with Retina Institute Japan, one of the RIKEN Ventures aiming to commercialize the world’s first practical applications of iPS cell technology.

Today, we are pleased to announce that we have signed a stock subscription agreement to acquire equity interest in Retina Institute Japan, K.K. (Head office: Fukuoka City, Fukuoka Prefecture; President and CEO: Hardy T S Kagimoto, MD; hereinafter “RIJ”) which aims to commercialize the world’s first practical applications of regenerative medicine using iPS cells*1. Based on this agreement, tella, Inc. (Head office: Chiyoda-ku, Tokyo; President & Representative Director: Yuichiro Yazaki; hereinafter “tella”) will provide capital totaling 100 million yen, with a payment date of April 10, 2013. RIJ is a recognized venture enterprise of the Independent Administrative Institution RIKEN, promoting research and development of new methods, using iPS cell-derived transplants of retinal pigment epithelial cells, for the treatment of age-related macular degeneration*2 and other blinding disorders for which there are insufficient therapies. About 80% of a person's sensory information is visually derived, and loss of sight makes daily living difficult. RIJ's R&D is aimed at reducing, however little, the disabilities of visually impaired patients. In February 2013 application was made to the Ministry of Health, Labour and Welfare for clinical study. There are high expectations for the world's first clinical study in regenerative medicine using iPS cells.

Led by DC vaccine therapy*3, tella promotes R&D related to regenerative and cell treatment, and via a collaborative relationship with RIJ will contribute to the development of leading-edge therapies. This matter will have only a negligible effect on results of operations in fiscal 2013.

TopPage